{"url":"https://lda.senate.gov/api/v1/filings/e8f8a2c7-84ea-4a63-bba6-c0ddfb4bb387/","filing_uuid":"e8f8a2c7-84ea-4a63-bba6-c0ddfb4bb387","filing_type":"RA","filing_type_display":"Registration - Amendment","filing_year":2021,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/e8f8a2c7-84ea-4a63-bba6-c0ddfb4bb387/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"James J Albertine","dt_posted":"2021-05-17T08:48:55-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"700 12th Street NW","registrant_address_2":"Suite 700","registrant_different_address":null,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":795,"url":"https://lda.senate.gov/api/v1/registrants/795/","house_registrant_id":31607,"name":"ALBERTINE ENTERPRISES, INC.","description":"Lobbyist","address_1":"700 12th STREET, N.W.","address_2":"Suite 700","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JAMES J ALBERTINE","contact_telephone":"","dt_updated":"2026-07-23T14:00:47.334117-04:00"},"client":{"id":210005,"url":"https://lda.senate.gov/api/v1/clients/210005/","client_id":1004366,"name":"GENETIC NETWORKS","general_description":"Pharmaceutical Research and Development","client_government_entity":false,"client_self_select":null,"state":"FL","state_display":"Florida","country":"US","country_display":"United States of America","ppb_state":"FL","ppb_state_display":"Florida","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-05-10"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Funding for cutting edge genetic development","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":42486,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"ALBERTINE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":42487,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"ALBERTINE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":102158,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":"S.","last_name":"FISHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Funding for cutting edge genetic development","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":42486,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"ALBERTINE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":42487,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"ALBERTINE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":102158,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":"S.","last_name":"FISHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}